VIVUS Earnings: Is This Biotech Ready for Prime Time?

VIVUS (Nasdaq: VVUS  ) not only beat its competitors, Arena Pharmaceuticals  (Nasdaq: ARNA  ) and Orexigen Therapeutics  (Nasdaq: OREX  ) , in making its obesity drug the first to reach patients -- it's also the first of this trio to report its Q3 earnings.

VIVUS posted its Q3 report before the market opened this morning, and unfortunately for shareholders, the company's results didn't meet the market's expectations. The company's net revenue was expected to top $300,000, but the drugmaker only raked in a little over $40,000. Earnings also took a bigger hit than expected, and VIVUS' shares subsequently plunged almost 25% today.

In the following video, health care analysts Max Macaluso and David Williamson discuss these stagnant sales and three ways that VIVUS can boost revenue in upcoming quarters.

The ravages of America's obesity epidemic are a challenge of epic proportions. However, a group of drug companies is looking to change everything. Newly approved drugs, including the one developed by VIVUS, could help to reverse this deadly course while reaping massive profits for investors in the process. The profit opportunity is immense but plenty of risks still exist, so make sure you understand the full story behind VIVUS in the Fool's brand new premium research service. It's such an important story that we have our top health care writer on the job, so make sure to secure a copy today by clicking here now.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2098691, ~/Articles/ArticleHandler.aspx, 12/20/2014 3:24:15 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement